There is a positive association between melanoma and Parkinson’s disease (PD), with the risk for melanoma ranging between 1.4- and 20-fold among individuals with PD. The risk is bidirectional, too, because there is also a 1.7- to 4.2-fold increased risk for PD in patients with melanoma. The link between PD and melanoma is not well understood, but increased expression of the PD-associated protein alpha-synuclein (?Syn) in melanoma cells may provide insight into the positive association between the two diseases.
Melanoma News
Study uncovers a way to boost treatment for aggressive melanoma
A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make one of the most aggressive forms of melanoma more treatable.
BRAFV600-mutant ctDNA as a Prognostic Biomarker in Resected Stage III Melanoma
1. ctDNA detection was found to have a relapse HR of 2.91 in the placebo and HR 2.98 in the treatment arm.
What to Know About Adjuvant Immunotherapy for Stage II/III Melanoma
Adjuvant immunotherapy with anti-PD-1 agents improves relapse-free survival in patients with stage II or III melanoma. But does everyone need treatment?